Do Sugar-Sweetened Beverages Increase Fasting FGF21 Irrespective of the Type of Added Sugar? A Secondary Exploratory Analysis of a Randomized Controlled Trial

• Published in: Nutrients Vol. 14; no. 19; p. 4169
• Main Authors: Geidl-Flueck, Bettina, Hochuli, Michel, Spinas, Giatgen A, Gerber, Philipp A
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.10.2022; MDPI
• Subjects: Analysis; Beverages; Body fat; Carbonated beverages; Cholesterol; Clinical trials; Development and progression; Dextrose; Disaccharides; Fasting; Fatty acids; FGF21; Fibroblast Growth Factors; Food; Fructose; Fructose - adverse effects; Glucose; Glucose - metabolism; Growth factors; Health aspects; Humans; Information management; Insulin; Intervention; Laboratories; Lipid metabolism; Lipids; liver; Male; Males; Metabolic disorders; Metabolic syndrome; Metabolic Syndrome - etiology; Metabolic syndrome X; Obesity; Peptides; Physiological aspects; Risk factors; Sucrose; Sucrose - adverse effects; Sugar; sugar-sweetened beverage; Sugar-Sweetened Beverages - adverse effects; Sugars; Triglycerides; Type 2 diabetes; Germany; France; United States > US; healthy men; homeostasis; glucose; liver; sugar-sweetened beverage; fructose; sucrose; FGF21; randomized controlled trial
• ISSN: 2072-6643; 2072-6643
• DOI: 10.3390/nu14194169

Human fibroblast growth factor 21 (FGF21) is a multifaceted metabolic regulator considered to control sugar intake and to exert beneficial effects on glucose and lipid metabolism. Elevated serum FGF21 levels are associated with metabolic syndrome, suggesting a state of FGF21 resistance. Further, given the evidence of a hepatic ChREBP and FGF21 signaling axis, it can be assumed that SSBs containing fructose would possibly increase FGF21 concentrations. We investigated the effects of sugar-sweetened beverage (SSB) consumption on fasting FGF21 levels in healthy, lean men, discriminating the effects of glucose, fructose, and their disaccharide sucrose by secondary data analysis from a randomized controlled trial. Seven weeks of daily SSB consumption resulted in increased fasting FGF21 in healthy, lean men, irrespective of the sugar type. Medians of ΔFGF21 between post-SSB intervention values (week 7) and no-intervention period values (IQR) in pg/mL were: glucose 17.4 (0.4-45.8), fructose 22.9 (-8.6-35.1), and sucrose 13.7 (2.2-46.1). In contrast, this change in FGF21 concentration was only 6.3 (-20.1-26.9) pg/mL in the control group. The lack of a fructose-specific effect on FGF21 concentrations is contrary to our assumption. It is concluded that SSB intake may impact FGF21 concentrations and could contribute to the increased FGF21 concentrations observed in subjects suffering from metabolic syndrome that is possibly associated with decreased FGF21 responsiveness.